To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial
Authors:
- A. OscarssonAOA. Oscarsson
- A. GuptaAGA. Gupta
- M. FredriksonMFM. Fredrikson
- J. JärhultJJJ. Järhult
- M. NyströmMNM. Nyström
- E. PetterssonEPE. Pettersson
- B. DarvishBDB. Darvish
- H. KrookHKH. Krook
- E. SwahnESE. Swahn
- C. EintreiCEC. Eintrei
- 1 March 2010
- journal article
- research article
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 104 (3) , 305-312
Abstract
Major adverse cardiac events (MACEs) are a common cause of death after non-cardiac surgery. Despite evidence for the benefit of aspirin for secondary prevention, it is often discontinued in the perioperative period due to the risk of bleeding. We conducted a randomized, double-blind, placebo-controlled trial in order to compare the effect of low-dose aspirin with that of placebo on myocardial damage, cardiovascular, and bleeding complications in high-risk patients undergoing non-cardiac surgery. Aspirin (75 mg) or placebo was given 7 days before surgery and continued until the third postoperative day. Patients were followed up for 30 days after surgery. A total of 220 patients were enrolled, 109 patients received aspirin and 111 received placebo. Four patients (3.7%) in the aspirin group and 10 patients (9.0%) in the placebo group had elevated troponin T levels in the postoperative period (P=0.10). Twelve patients (5.4%) had an MACE during the first 30 postoperative days. Two of these patients (1.8%) were in the aspirin group and 10 patients (9.0%) were in the placebo group (P=0.02). Treatment with aspirin resulted in a 7.2% absolute risk reduction [95% confidence interval (CI), 1.3-13%] for postoperative MACE. The relative risk reduction was 80% (95% CI, 9.2-95%). Numbers needed to treat were 14 (95% CI, 7.6-78). No significant differences in bleeding complications were seen between the two groups. In high-risk patients undergoing non-cardiac surgery, perioperative aspirin reduced the risk of MACE without increasing bleeding complications. However, the study was not powered to evaluate bleeding complications.Keywords
This publication has 25 references indexed in Scilit:
- Coronary-Artery StentsNew England Journal of Medicine, 2006
- Low‐dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta‐analysisJournal of Internal Medicine, 2005
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Thromboelastography for Monitoring Prolonged Hypercoagulability After Major Abdominal SurgeryAnesthesia & Analgesia, 2001
- Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarctionJACC, 2000
- Abnormally high platelet activity after discontinuation of acetylsalicylic acid treatmentBlood Coagulation & Fibrinolysis, 1996
- Aspirin, a Silent Risk Factor in UrologyScandinavian Journal of Urology and Nephrology, 1995
- Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery diseaseThe Lancet, 1990
- Perioperative Cardiac MorbidityAnesthesiology, 1990
- Preoperative Aspirin Ingestion Increases Operative Blood Loss after Coronary Artery Bypass GraftingThe Annals of Thoracic Surgery, 1988